Drug guidance
GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
Condition
Endocrine and metabolic
19 December 2022
Published on 19 Dec 2022
Last Updated on 19 Dec 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen for treating type 2 diabetes mellitus:
as a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated; and
in combination with insulin and metformin, unless metformin is contraindicated or not tolerated.
Funding status
Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 February 2023.
MAF assistance does not apply to any formulations or strengths of liraglutide or semaglutide for treating type 2 diabetes mellitus.